Suppr超能文献

二甲基苯基三氮烯CB10-277的临床前、I期和药代动力学研究。

Preclinical, phase I and pharmacokinetic studies with the dimethyl phenyltriazene CB10-277.

作者信息

Foster B J, Newell D R, Carmichael J, Harris A L, Gumbrell L A, Jones M, Goodard P M, Calvert A H

机构信息

Institute of Cancer Research, Sutton, Surrey, UK.

出版信息

Br J Cancer. 1993 Feb;67(2):362-8. doi: 10.1038/bjc.1993.66.

Abstract

Decarbazine is an imidazole dimethyltriazene with reproducible activity in patients with metastatic melanoma. CB10-277 is a phenyl dimethyltriazene which, like dacarbazine, requires metabolic activation to its corresponding monomethyl species for antitumour activity. In preclinical models (human melanoma xenografts and transplantable rodent tumours) CB10-277 showed a similar spectrum and level of activity when compared to dacarbazine. Pharmacokinetic studies were performed with CB10-277 in mice treated i.v. at the LD10 (750 mg m-2) and plasma analysed by HPLC. The parent drug area under the plasma concentration vs time curve (AUC) was 142 mM x minutes. Drug metabolism occurred as evidenced by the HPLC identification of the monomethyl species (AUC = 8 mM x minutes) as well as other metabolites. A Phase I trial using a short infusion with doses repeated every 21 days has been performed. Thirty-six patients received 80 courses over a dose range of 80-6,000 mg m-2. The dose limiting toxicity was nausea and vomiting which occurred in 80% of the evaluable courses > or = 900 mg m-2. The only other common side effect was a flushing or warm sensation, which occurred in over 75% of courses at > or = 1,350 mg m-2. There were no hemodynamic consequences. Responses occurred in patients with melanoma (one complete, two partial, one mixed/11), sarcoma (one mixed/6) and carcinoid (one partial/l). Pharmacokinetics were performed in 46 courses. The CB10-277 AUC increased linearly with dose (r = 0.9203, P < 0.001) up to 700 mM x minutes at 6,000 mg m-2). Evidence of CB10-277 metabolism was observed, as in mice, by detection of the monomethyl species and other metabolites. However, the plasma levels of the monomethyl species in patients (1.8 and 3.7 mM x minutes at 6,000 mg m-2) were less than those predicted from studies in mice. Despite this, antitumour activity in dacarbazine sensitive histologies was observed and additional studies with CB10-277 are recommended.

摘要

达卡巴嗪是一种咪唑二甲基三氮烯,对转移性黑色素瘤患者具有可重复的活性。CB10 - 277是一种苯基二甲基三氮烯,与达卡巴嗪一样,需要代谢活化为相应的单甲基衍生物才能发挥抗肿瘤活性。在临床前模型(人黑色素瘤异种移植瘤和可移植的啮齿动物肿瘤)中,与达卡巴嗪相比,CB10 - 277显示出相似的活性谱和活性水平。对静脉注射LD10(750 mg m-2)处理的小鼠进行了CB10 - 277的药代动力学研究,并通过高效液相色谱法分析血浆。血浆浓度-时间曲线下的母体药物面积(AUC)为142 mM·分钟。通过高效液相色谱法鉴定单甲基衍生物(AUC = 8 mM·分钟)以及其他代谢产物,证明了药物代谢的发生。已经进行了一项I期试验,采用短时间输注,每21天重复给药一次。36名患者在80 - 6,000 mg m-2的剂量范围内接受了80个疗程的治疗。剂量限制性毒性是恶心和呕吐,在≥900 mg m-2的可评估疗程中有80%出现。唯一的其他常见副作用是脸红或温热感,在≥1,350 mg m-2的疗程中有超过75%出现。没有血液动力学方面的影响。黑色素瘤患者(1例完全缓解、2例部分缓解、1例混合缓解/11例)、肉瘤患者(1例混合缓解/6例)和类癌患者(1例部分缓解/1例)出现了反应。在46个疗程中进行了药代动力学研究。CB10 - 277的AUC随剂量线性增加(r = 0.9203,P < 0.001),在6,000 mg m-2时达到700 mM·分钟。与小鼠研究一样,通过检测单甲基衍生物和其他代谢产物观察到了CB10 - 277代谢的证据。然而,患者体内单甲基衍生物的血浆水平(6,000 mg m-2时为1.8和3.7 mM·分钟)低于小鼠研究预测的水平。尽管如此,在对达卡巴嗪敏感的组织学类型中观察到了抗肿瘤活性,建议对CB10 - 277进行进一步研究。

相似文献

本文引用的文献

1
Antitumor activity of triazenoimidazoles.三氮烯咪唑类化合物的抗肿瘤活性。
Biochem Pharmacol. 1962 Jul;11:674-6. doi: 10.1016/0006-2952(62)90130-2.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验